Prince Mario-Max Schaumburg-Lippe: Humanitas Launches With LSU DeepDrug AI License

Most company launches get a ribbon, a photo and a quiet press release. Humanitas Global Health picked a bigger room. The company announced its launch on Tuesday, October 27, 2026, in New Orleans, during the American Association of Pharmaceutical Scientists 2026 PharmSci 360 conference, and it arrived with a signed license in hand: an agreement to commercialize DeepDrug technologies from Louisiana State University.

The pitch is refreshingly plain. Humanitas calls itself a mission-driven initiative that applies explainable, traceable artificial intelligence and strong science to reduce preventable suffering and widen access to better care. In practice, that means turning university research into working tools that speed up drug development, improve medication safety and help clinicians make more precise decisions at the point of care.

Software that has to show its work

DeepDrug was developed at LSU by a team led by Professor Supratik Mukhopadhyay. The platform brings together artificial intelligence, molecular design and predictive modeling to help researchers discover and evaluate potential medicines before years and budgets disappear into dead ends. Plenty of AI tools will hand you a prediction. Fewer will show you the reasoning you can actually test.

That is the part Humanitas keeps coming back to. Its discovery approach links each prediction to physicochemical properties and to pharmacologic and toxicologic mechanisms that can be checked in the lab. A candidate compound is not just ranked. It comes with an explanation a scientist can poke, prod and try to prove wrong, which is exactly how good science is supposed to work. It is the same demand for systems that can explain themselves that readers saw in ZWAG AI putting every language first in Dubai, where checking output in real time mattered more than sounding fluent.

“Humanitas was founded on a simple conviction: scientific progress should translate into less suffering and better care,” said Chris Galliano, the company’s founder and chief executive officer. “Our launch and the LSU license agreement bring together the science, technology, and commitment needed to move promising discoveries toward practical use. Humanitas is focused not just on what artificial intelligence can predict, but on how those predictions can be tested, trusted, and used to help people.”

From the lab bench to the medicine list

The second half of the plan tackles a quieter problem, one that sits in almost every clinic. Patients often take several medicines at once, and some combinations do not get along. Humanitas is advancing InteractIQ, an auditable AI platform that reviews a patient’s complete medication list to flag clinically meaningful risks from drug-drug interactions. The company is validating it retrospectively with real-world electronic health record data from LCMC Health, with a stated aim that should please every busy prescriber: surface the risks that matter, and cut down the unhelpful alerts that staff learn to ignore.

LSU sees the deal as proof of what a research university is for. “As someone who spent years in drug development, I know that a medicine is only as good as our ability to use it safely,” said James Dalton, PhD, chancellor of Louisiana State University. “This license puts LSU research to work for patients and shows exactly why our goal of becoming a top 50 research university matters: more discoveries like this one, reaching the people who need them.” Industrial AI is learning the same lesson about trust and verification, as Honeywell AI bringing a $60M upside case to the Dangote refinery showed this week.

Ethical Intelligence, spelled out

Humanitas gave its design philosophy a name: Ethical Intelligence, or EI. The idea is to build ethical principles and respect for human dignity into the system itself, not bolt them on later. Outputs should rest on verifiable data. When the evidence runs thin, the system should say so and acknowledge uncertainty rather than speculate or make something up. Human oversight stays in the loop.

“AI that cannot explain its conclusions or distinguish evidence from speculation has no place in medicine,” Galliano said. “Ethical Intelligence puts humanity first by making its reasoning transparent, grounding its outputs in evidence, and preserving human oversight, so clinicians, scientists, and patients can make informed decisions.”

A full Tuesday in New Orleans

The timing was deliberate. PharmSci 360 runs October 25-28 at the Ernest N. Morial Convention Center, and Humanitas filled its launch day. At 12:30 p.m. on October 27 the company hosted a panel discussion on turning AI innovation into better care, introducing its mission, the DeepDrug and InteractIQ platforms and its commercialization priorities. At 2:30 p.m. it attended the Louisiana Biotechnology Innovation Award ceremony, which honored LSU and the DeepDrug team for advances in drug discovery and prescription drug safety. Anyone who missed New Orleans gets another chance soon: Humanitas will hold an introductory webcast on Tuesday, November 10, 2026, at 8:30 a.m. EST.

So what should readers watch next? Three concrete things. First, the InteractIQ validation results from the LCMC Health data, because retrospective proof is where medication-safety tools earn their credibility. Second, which DeepDrug candidates move into focused preclinical work now that a commercial license sits behind them. Third, whether other universities follow LSU’s lead and license explainable platforms instead of letting strong research sit on a shelf. A launch is a promise. This one, at least, came with names, dates and a mechanism attached.

Also published on: